Miscellaneous

Rituximab Acellbia 100-500 mg. Price, reviews

click fraud protection

Content

  1. Release form
  2. Composition of the preparation
  3. Pharmacological properties
  4. Pharmacodynamics and pharmacokinetics
  5. Indications for use
  6. Contraindications
  7. At what age can the drug be used?
  8. Instructions for use, dosage
  9. Side effects
  10. Overdose
  11. special instructions
  12. Drug interactions
  13. Analogs
  14. Terms, conditions of sale and storage
  15. Price
  16. Rituximab video

Acellbia is a medicine, which is produced by the Russian pharmaceutical company CJSC Biocad. This medication is available in a therapeutic dosage of 10 mg. Acellbia belongs to the category of drugs based on monoclonal bodies with anti-tumor properties. The price of this medication, which was created to fight cancer, is within 10 thousand. rub.

Release form

The drug Acellbia is available in the form of a drug concentrate for self-preparation of intravenous infusion. Outwardly, this solution looks like a completely transparent or slightly yellowish liquid. The filling of the medicinal product is carried out in vials with a capacity of 10, 20 and 50 ml, depending on the individual needs of each patient. The main packaging of the drug is a cardboard box.

insta story viewer

Composition of the preparation

Acellbia is an antineoplastic agent that contains the active substance rituximab at a concentration of 10 mg. In the process of preparing the finished medication for intravenous infusion, a sterile solution of sodium chloride with a concentration of 0.9% is used. This component serves as an auxiliary function, acting as a universal solvent. The price of this additional substance is from 27 rubles. per bottle with a capacity of 200 ml.

Pharmacological properties

Acellbia is a new generation drug that has the following pharmacological properties:

  • starts the process of lysis of lymphocytes with signs of cancer;
  • prevents metastasis of cancer cells from the blood into the structure of the musculoskeletal system and tissues of internal organs;
  • promotes the replacement of cancerous B-lymphocytes with healthy cells of the circulatory system;
  • circulates in plasma in the form of free antigen;
  • does not penetrate into the intracellular space of blood cells, and also does not violate the integrity of their membrane, which minimizes the risk of side effects in the hematology line;
  • increases the cytotoxic sensitivity of reborn lymphoma cells to chemotherapeutic drugs (due to this property of Acellbia, the therapeutic efficacy of medicines of this groups);
  • reduces the number of oncological B-cells after the first injection of the infusion solution, which improves the patient's general well-being;
  • increases the resistance of the patient's immunity in the fight against mutated cells of the circulatory system.

Rituximab Acellbia 100-500 mg. Instructions for use, priceAcellbia 10 mg (the price of this medication is above average) shows positive pharmacological properties in the treatment of patients with chronic lymphocytic leukemia and non-Hodgkin lymphoma. The dynamics of the therapeutic action of the drug depends on the stage of the oncological disease and the timeliness of the patient's appeal to the attending physician.

Pharmacodynamics and pharmacokinetics

The pharmacodynamics of the drug Acellbia is due to the biochemical properties of its active substance in the form of rituximab. It is a monoclonal antibody found in both mice and humans. A biologically active component of this type builds strong bonds with the CD 20 antigen, which has a transmembrane structure. This element is found on the surface of pre-B-lymphocytes and in mature B-lymphocytes.

At the same time, this antigen is completely absent in hematopoietic cell structures, plasma cells with a normal structure, as well as in pro-B cells. In 95% of cases, rituximab is expressed in the blood of patients with non-Hodgkin's lymphoma.

The monoclonal body, which has passed the stage of expression, is located on the CD 20 cell, forms a molecular bond with antibody, and then it is not neutralized, but simply ceases to penetrate into the intracellular space and through the membrane the affected cell. The uniqueness of the pharmacodynamic properties of the drug Acellbia lies in the fact that its active component rituximab combines with the CD 20 antigen on the surface of mutated B-lymphocytes. In response to this process, the patient's body triggers an immunological reaction to destroy this type of B-cells. Lysis of cancerous lymphocytes is activated instantly.

The restoration of the number of healthy B cells without signs of their defeat by the oncological process occurs after 6 months. from the beginning of the course therapy with Acellbia. Complete normalization of the cellular composition of the blood, which was disturbed by a hematological disease of a malignant nature, is observed no earlier than 1 year after the completion of treatment.

In patients with a severely weakened organism, the presence of concomitant pathologies of internal organs, the period of total restoration of B-cells may take a longer period of time. Upon completion of therapy with Acellbia, anti-chimeric antibodies were detected in 1% of patients with non-Hodgkin's lymphoma.

The pharmacokinetics of the antineoplastic agent Acellbia is the same for patients of all age categories, gender and race. The maximum concentration of rituximab in the blood plasma increases after the next intravenous infusion. A decrease and an increase in the percentage of this substance in the patient's body has a proportional correlation with the number of healthy B cells and the severity of the tumor process. The median of this drug is higher than in patients who have histological types of malignant neoplasms B, C, and D.

According to the data of clinical trials of the drug Acellbia, traces of its active substance rituximab are found in the body of patients after 3-6 months. after completion of infusion therapy. The presence of this pharmacokinetic index indicates the accumulative effect of the antitumor agent. The manufacturer of this medication does not have information on the nature of the therapeutic effect of Acellbia solution on the body of patients with renal or hepatic insufficiency.

Indications for use

Acellbia 10 mg (the price of the infusion concentrate depends on the general trends in the pharmaceutical market products) is used as a monotherapeutic agent or in combination with drugs chemotherapy.

This medication is prescribed for a course admission in the following cases:

  • a chronic form of recurrent lymphocytic leukemia, the development of which is accompanied by the resistance of the affected B cells to the effects of chemotherapeutic drugs;
  • malignant hematological pathologies in which the patient has not previously received standard antitumor therapy;
  • follicular lymphoma;
  • non-Hodgkin's lymphoma with signs of recurrence and increased resistance to chemotherapy drugs (in in this case, the medication is used to treat hematological tumors of varying degrees malignancy).

Based on the results of the patient's examination, the attending oncologist decides on the use of the solution Acellbia as a monotherapeutic agent, or else conducts its simultaneous combination with chemistry preparations. For each patient, an individual scheme of antitumor infusion injections is built, in between which a comprehensive study of the patient's blood is performed.

Contraindications

Acellbia 10 mg (the price of this medicine is unaffordable for people without a steady income) has a small number of contraindications.

This drug is not used in the following cases:

  • an allergic reaction to rituximab or an individual intolerance to the patient's mouse proteins (the active substance of this medication is obtained from the body of these rodents);
  • all types of infectious diseases that are acute;
  • immunodeficiency of the primary or secondary type;
  • the state of pregnancy, regardless of the period of intrauterine development of the fetus;
  • lactation period of a newborn baby by breastfeeding;
  • the patient is under 18 years of age.

The drug Acellbia is used with extreme caution in relation to patients who have the following body examination results:

  • respiratory failure detected;
  • tumor lesion of the lungs or their infiltration with metastases;
  • high level of tumor load;
  • the total number of malignant B cells that circulate in the blood exceeds 25 thousand. μl;
  • neutropenia with an indicator below 1500 μl;
  • chronic bacterial, viral, or fungal infections that drain the patient's immune system;
  • thrombocytopenia.

Patients with the above pathologies, who were nevertheless prescribed treatment with Acellbia, should be under round-the-clock supervision of medical personnel. In this case, there is a risk of deterioration in their well-being caused by an exacerbation of concomitant diseases.

At what age can the drug be used?

The antineoplastic agent Acellbia is used to treat patients over the age of 18. Elderly people who have been diagnosed with a hematological disease of malignant etiology do not need special correction of the dosage regimen.

Instructions for use, dosage

Acellbia 10 mg (the price of this medication is not higher than that of other antineoplastic agents) is prepared under sterile conditions of a medical institution. The required volume of the antitumor concentrate is diluted in a vial with a solution for infusion therapy in the form of sodium chloride with 0.9% concentration. The finished product should have a mass fraction of the anticancer agent in the range from 1 to 4 mg per 1 ml of intravenous solution. While mixing the constituent substances of the medication, it is necessary to smoothly turn the bottle up and down, but at the same time make sure that no foam forms inside the bubble.Rituximab Acellbia 100-500 mg. Instructions for use, price

The prepared solution based on Acellbia concentrate is used immediately. There are no synthetic and natural preservatives in the composition of this medication. In room conditions, the finished product exhibits chemical and physical stability no longer than 12 hours from the moment of its preparation.

At temperatures from +2 to +8 ° C, the anticancer agent can be stored for no more than 1 day. The prepared medication is injected into the patient's circulatory system intravenously using a separate catheter. The first infusion is carried out at a rate of 50 μg in 60 seconds. Then every 30 minutes. this indicator is gradually increased by another 50 μg in 60 s. The maximum drip rate of the drug is 400 μg in 60 s.

Subsequent intravenous infusions begin at a rate of no more than 100 μg in 60 seconds. After 30 minutes. the catheter is adjusted, increasing its throughput by an additional 100 µg in 60 s. Anticancer solution Acellbia is contraindicated for intravenous administration by a jet or bolus method.

During treatment with this medication, it is forbidden to reduce its therapeutic doses in patients who do not have signs of side effects or individual intolerance. An unreasonable decrease in the concentration of rituximab in the blood plasma may lead to a decrease in the antitumor effect.

Monotherapy with Acellbia drug provides for its use at a dosage of 375 mg per m2 no more than once every 7 days. The duration of the therapeutic course is 4 weeks. The selection of doses of this medication is carried out by an oncologist depending on the patient's body weight, tumor load, and the number of cancer cells in his blood. In combination with chemistry preparations, Acellbia is taken in cycles. On the first day of treatment, the patient receives 375 mg per m2 of anticancer solution. Then, anti-inflammatory drugs from the group of glucocorticosteroids are injected into his body. The patient is then given an intravenous infusion of chemotherapy medication.

Combination treatment with Acellbia anticancer concentrate and chemotherapeutic drugs is carried out for 6-8 cycles. The duration of 1 cycle is 21 or 28 days, depending on the severity of the cancer, the presence or absence of positive dynamics towards recovery.

During combination therapy, the following drugs are used together with Acellbia medication:

  • Prednisolone;
  • Mitoxantrone;
  • Cyclophosphamide;
  • Chlorambucil;
  • Teniposide;
  • Interferon;
  • Vincristine.

The next cycle of combined therapy with Acellbia concentrate, chemistry drugs and glucocorticosteroids may contain a different set of medications. The treatment regimen is developed by the oncologist individually for each patient. Maintenance monotherapy with Acellbia solution involves the use of a standard dose of 375 mg per 1 m2 with the frequency of intravenous administration once every 60 days for no more than 2 years (a total of 12 drip infusions).

Side effects

In medical practice, there have been cases when the manifestation of side effects of the drug Acellbia was observed in patients for 12 months. after cessation of infusion therapy.

During the period of therapy with this medication, the occurrence of the following symptoms is not excluded:

  • bacterial pneumonia;
  • septic blood poisoning;
  • decrease in the protective functions of the immune system to a critical level;
  • leukopenia;
  • the development of herpes infection;
  • viral and bacterial infection of the respiratory system;
  • aplastic anemia;
  • thrombocytopenia;
  • hypoxia;
  • compressive pains inside the chest;
  • lymphadenopathy;
  • attacks of bronchial asthma;
  • allergic rhinitis;
    Rituximab Acellbia 100-500 mg. Instructions for use, price
    Rituximab Acellbia
  • dyspnea;
  • angioedema;
  • hematological disorders associated with the rate of blood clotting;
  • swelling of facial tissues;
  • rapid weight loss;
  • increased blood sugar levels;
  • headache;
  • nausea;
  • discharge of vomit;
  • a feeling of chills and fever;
  • loss of appetite;
  • diarrhea;
  • an increase in the volume of the abdomen;
  • increased blood pressure;
  • dysphagia;
  • stomatitis;
  • tachycardia;
  • constipation;
  • physical weakness and fatigue;
  • asthenia;
  • angina pectoris;
  • heart failure;
  • acute pain in the area of ​​injection of the drug;
  • bradycardia;
  • calcium deficiency in the body;
  • increased nervous irritability;
  • irritability;
  • depressive state;
  • hives;
  • the appearance on the skin of multiple red or pink rash, which is accompanied by itching;
  • sense of anxiety;
  • hair loss;
  • increased sweating;
  • pain and tinnitus.

The above side effects of the drug Acellbia may be accompanied by a change in the cellular composition of the blood. Patients diagnosed with individual sensitivity or complete intolerance to rituximab are observed by the attending doctor. The oncologist decides whether to continue or discontinue therapy with this medication, depending on the symptoms detected.

Overdose

In case of an overdose with Acellbia, symptoms may appear that correspond to side effects. The severity of pathological symptoms depends on how much the therapeutic dosage regimen has been violated.

special instructions

During therapy with Acellbia anticancer concentrate, you must remember the following instructions, which were drawn up by the manufacturer of this medication:

  • infusion of the solution should be carried out only under the supervision of an oncologist or a specialist in the field of hematology;
  • the first 30 minutes. - 2 hours of the first intravenous administration of rituximab, fever and chills may occur;
  • a patient receiving anticancer therapy must be in the hospital of a medical institution, which is equipped with a ward for emergency resuscitation measures;
  • severe reactions of the patient's body in response to the infusion of the drug include angioedema, attacks of severe headache, urticaria, destabilization of blood pressure;
  • due to the high risk of developing anaphylaxis, a set should be in the patient's room anti-shock medicines, which necessarily includes adrenaline, antihistamines and glucocorticosteroids.

In patients with a large tumor load, malignant cell lysis syndrome may develop when under the action of rituximab in a short period of time leads to the death of too many reincarnated lymphocytes. In this case, a critical load on the kidneys is created, the balance of blood electrolytes is disturbed, a state of hypocalcemia, hyperkalemia, hyperphosphatemia, hyperuricemia develops.

Drug interactions

There is no scientifically confirmed information on the drug interaction of Acellbia with medicines of other pharmacological groups. The simultaneous use of an antitumor concentrate with solutions based on monoclonal bodies increases the risk of an allergic reaction.

Analogs

The table below lists the main analogues of the drug Acellbia, and also indicates their average cost.Rituximab Acellbia 100-500 mg. Instructions for use, price

Antineoplastic name Price
Mabthera RUB 27810
Redditux RUB 2900

The above medications are used as monotherapeutic agents, or are included in a combined course of anticancer treatment.

Terms, conditions of sale and storage

Acellbia is a prescription drug. The general shelf life of the drug is 2 years 6 months. provided that it is stored in its original packaging at a temperature range of + 2... 8 ° С.

Price

The average cost of the Acellbia anticancer concentrate is 10,000 rubles. per package with 2 bottles inside.

Acellbia 10 mg is a drug used to treat blood cancers. This medication is available in the form of a liquid concentrate. The preparation of the finished therapeutic product is carried out before its direct use.

The anticancer concentrate is mixed with the infusion solution. Acellbia is injected intravenously through an individual catheter by the drip method. Jetting the solution is contraindicated. This medication is effective in the treatment of non-Hodgkin's lymphoma and B-cell damage from chronic lymphocytic leukemia. The high price of an anticancer drug fully justifies its therapeutic properties.

Rituximab video

Rituximab in treatment:

  • Share
How to remove drugs from the body quickly, how much they leave, harm
Miscellaneous

How to remove drugs from the body quickly, how much they leave, harm

ContentIndicationsContraindicationsUltra-Rapid Opioid DetoxificationTrainingProcedure step by stepDo's and Don'ts AfterHow long will the result las...

Ascorutin for adults. Instructions on how to take
Miscellaneous

Ascorutin for adults. Instructions on how to take

ContentRelease formChemical compositionPharmacological propertiesPharmacodynamics and pharmacokineticsIndications for useContraindicationsInstructi...

Piracetam tablets. Indications, instructions for use, price, reviews
Miscellaneous

Piracetam tablets. Indications, instructions for use, price, reviews

ContentRelease formChemical compositionPharmacological propertiesPharmacodynamics and pharmacokineticsIndications for useContraindicationsAt what a...